Benson Seth Benjamin 4
4 · HARVARD BIOSCIENCE INC · Filed Jun 11, 2026
Research Summary
AI-generated summary of this filing
Harvard Bioscience (HBIO) Director Seth Benson Receives Restricted Stock Award
What Happened Benson Seth Benjamin, a director of Harvard Bioscience, was granted 16,556 restricted stock units (RSUs) on June 9, 2026. The grant is recorded at $0.00 per share (transaction code A — award/acquisition). These RSUs vest in full either immediately prior to the company’s next annual meeting or one year from the grant date, whichever is earlier.
Key Details
- Transaction date and type: 2026-06-09 — Grant/Award of 16,556 RSUs at $0.00 (Form 4 filed 2026-06-11).
- Shares beneficially owned after transaction: 27,556 total (includes the 16,556 RSUs plus 11,000 shares already beneficially owned, per filing).
- Footnote highlights:
- F1: Vesting: full vesting immediately before next annual meeting or one year from grant, whichever is earlier.
- F2: The reported beneficial ownership combines this award and 11,000 previously owned shares.
- F3: A 10-for-1 reverse stock split effective March 13, 2026 adjusted prior reported quantities (numbers shown are post-split).
- Timeliness: Filed June 11, 2026 for a June 9 transaction — reported within the normal two-business-day Form 4 window.
Context This was a compensation award (RSUs), not an open-market purchase or sale; RSUs typically reflect compensation or retention incentives and do not represent immediately tradeable shares until vested. No exercise, sale, or cashless transaction occurred in this reported grant.
Insider Transaction Report
Form 4
Benson Seth Benjamin
Director
Transactions
- Award
Common Stock
[F1][F2][F3]2026-06-09+16,556→ 27,556 total
Footnotes (3)
- [F1]Represents an award of 16,556 restricted stock units that vests in full (i) immediately prior to the Company's next annual meeting; or (ii) one year from the date of grant, whichever is earlier.
- [F2]Includes (a) the award described in footnote (1) above and (b) 11,000 shares of common stock beneficially owned by the Reporting Person.
- [F3]On March 13, 2026, the common stock of Harvard Bioscience, Inc. underwent a reverse stock split in a ratio of 10-for-1. The 11,000 shares referenced in Footnote 2(b) were previously reported as covering 110,000 restricted stock units (which have now vested) and are beneficially owned by the Reporting Person. These numbers have been adjusted to reflect the stock split that occurred on March 13, 2026.
Signature
/s/ Seth Benson|2026-06-11